Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Comment by Silky_Johnsonon Apr 13, 2021 1:03am
234 Views
Post# 32983203

RE:Painful selloff here today....

RE:Painful selloff here today....

I believe you are getting a bargain here. Likely a sell off in relation to Think Equity exercising its over allotment of shares. They now have ~$28 million USD in the bank so they are almost trading at cash value. 


The previous trial data was good and now they have money to dose more patients for an eventual big pharma buyout. My guess is it will be Incyte down the road considering we are using their checkpoint inhibitor in our combination studies. 


They are also kicking off their HLA matching program Bria OTS which could be a really big winner. The science has always been good and now they have the money. 

Cheers,
Silky

<< Previous
Bullboard Posts
Next >>